-+ 0.00%
-+ 0.00%
-+ 0.00%
*Immunovant: In Light of Evolving Sjögren's Disease Landscape and Recent Data in the Field, Expect It Is Unlikely That We Will Advance IMVT-1402 Further in SjD Beyond the Ongoing, Fully Enrolled Phase 2 Trial >IMVT
Share

Please log in to view news

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending